| Role of the IL-23/IL-17 pathway in rheumatic diseases: an overview C Schinocca, C Rizzo, S Fasano, G Grasso, L La Barbera, F Ciccia, ... Frontiers in immunology 12, 637829, 2021 | 266 | 2021 |
| Rituximab in the treatment of inflammatory myopathies: a review S Fasano, P Gordon, R Hajji, E Loyo, DA Isenberg Rheumatology 56 (1), 26-36, 2017 | 144 | 2017 |
| Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus … S Fasano, L Pierro, I Pantano, M Iudici, G Valentini The Journal of rheumatology 44 (7), 1032-1038, 2017 | 119 | 2017 |
| Early disease and low baseline damage as predictors of response to belimumab in patients with systemic lupus erythematosus in a real‐life setting M Gatto, F Saccon, M Zen, F Regola, M Fredi, L Andreoli, A Tincani, ... Arthritis & Rheumatology 72 (8), 1314-1324, 2020 | 118 | 2020 |
| Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: Symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus … V Restivo, S Candiloro, M Daidone, R Norrito, M Cataldi, G Minutolo, ... Autoimmunity Reviews 21 (1), 102925, 2022 | 79 | 2022 |
| Autoimmune gastrointestinal complications in patients with systemic lupus erythematosus: case series and literature review SC Alves, S Fasano, DA Isenberg Lupus 25 (14), 1509-1519, 2016 | 66 | 2016 |
| Precision medicine in systemic lupus erythematosus S Fasano, A Milone, GF Nicoletti, DA Isenberg, F Ciccia Nature Reviews Rheumatology 19 (6), 331-342, 2023 | 63 | 2023 |
| Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study M Iudici, S Fasano, L Gabriele Falcone, I Pantano, G La Montagna, ... Rheumatology 55 (9), 1623-1630, 2016 | 49 | 2016 |
| Pathogenesis of primary Sjögren’s syndrome beyond B lymphocytes S Fasano, D Mauro, F Macaluso, F Xiao, Y Zhao, L Lu, G Guggino, ... Clin Exp Rheumatol 38 (Suppl 126), S315-S323, 2020 | 46 | 2020 |
| Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review S Fasano, DP Margiotta, L Navarini, L Pierro, I Pantano, A Riccardi, ... Lupus 26 (14), 1463-1472, 2017 | 46 | 2017 |
| Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the … G Valentini, D Huscher, A Riccardi, S Fasano, R Irace, V Messiniti, ... Annals of the rheumatic diseases 78 (11), 1576-1582, 2019 | 45 | 2019 |
| Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort M Gatto, F Saccon, L Andreoli, E Bartoloni, F Benvenuti, A Bortoluzzi, ... Journal of Autoimmunity 124, 102729, 2021 | 40 | 2021 |
| Present and novel biologic drugs in primary Sjögren's syndrome S Fasano, DA Isenberg Clinical and experimental rheumatology 37 (S 118 (3)), 167-174, 2019 | 40 | 2019 |
| Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease M Iudici, I Pantano, S Fasano, L Pierro, B Charlier, M Pingeon, F Dal Piaz, ... Lupus 27 (2), 265-272, 2018 | 40 | 2018 |
| Bruton’s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE? A Lorenzo-Vizcaya, S Fasano, DA Isenberg ImmunoTargets and Therapy, 105-110, 2020 | 39 | 2020 |
| Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis L Ji, W Xie, S Fasano, Z Zhang Lupus science & medicine 9 (1), 2022 | 37 | 2022 |
| Prolonged remission is associated with a reduced risk of cardiovascular disease in patients with systemic lupus erythematosus: a GIRRCS (Gruppo Italiano di Ricerca in … S Fasano, DPE Margiotta, L Pierro, L Navarini, A Riccardi, A Afeltra, ... Clinical Rheumatology 38, 457-463, 2019 | 35 | 2019 |
| Which patients with systemic lupus erythematosus in remission can withdraw low dose steroids? Results from a single inception cohort study S Fasano, MA Coscia, L Pierro, F Ciccia Lupus 30 (6), 991-997, 2021 | 34 | 2021 |
| Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries M Iudici, S Fasano, D Iacono, B Russo, G Cuomo, G Valentini Clinical rheumatology 33, 153-164, 2014 | 32 | 2014 |
| The association between duration of remission, fatigue, depression and health-related quality of life in Italian patients with systemic lupus erythematosus DPE Margiotta, S Fasano, F Basta, L Pierro, A Riccardi, L Navarini, ... Lupus 28 (14), 1705-1711, 2019 | 31 | 2019 |
